Single-nucleotide variant profiling in liquid biopsy with RECO-Cas
Science Advances · 2026
DOI: 10.1126/sciadv.aed1757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Chong Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, CRISPR-Cas Systems, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, UConn Research Excellence Program award.
Abstract (Originalsprache)
Mutation detection of cell-free DNA (cfDNA) through liquid biopsy is essential for precision oncology, resistance profiling, and informed clinical decision-making. However, its clinical application has remained limited by the lack of simple, rapid, accurate, and cost-effective detection approaches. Here, we report a recombined DNA construct–activated Cas12a (RECO-Cas) assay for profiling cfDNA mutations. The RECO-Cas assay uses a recombined DNA construct generated from Argonaute-nicked mutant DNA and an artificial DNA activator to selectively trigger CRISPR-Cas12a, enabling 0.01% variant allele frequency sensitivity and single-nucleotide resolution. Using the assay, we detect KRAS , EGFR , and PIK3CA point mutations in cfDNA from clinical plasma samples, demonstrating high sensitivity (90.48%) and excellent specificity (100%). We also apply it to successfully classify and identify KRAS missense variants. RECO-Cas provides a simple, rapid, and affordable solution that is compatible with a compact, wirelessly powered point-of-care diagnostic platform incorporating smartphone-based fluorescence detection. This assay enables highly sensitive and specific detection of low-frequency mutations, facilitating early cancer diagnosis and supporting the development of personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA.
- Department of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.
- Research Tissue Repository, University of Connecticut Health Center, Farmington, CT 06030, USA.
- Department of Public Health Sciences, University of Connecticut Health Center, Farmington, CT 06030, USA.
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Chong Guo, Ramachandra Yerramsetti, Jiongyu Zhang, Xin Guan, Rui Yang, Chengyu Hou, Minjie Pei, Kurt T Schalper, Ziyue Li, Wenqi Gan, Omar Ibrahim, Rachael A Clark, Changchun Liu
Förderung
- NCI NIH HHS
- National Institutes of Health
- UConn Research Excellence Program award
Zitieren
APA
Guo, C., Zhang, S., Yerramsetti, R., Zhang, J., Guan, X., Yang, R., Hou, C., Pei, M., Schalper, K. T., Liu, X., Li, Z., Perpetua, L., Gan, W., Ibrahim, O., Clark, R. A., & Liu, C. (2026). Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science Advances. https://doi.org/10.1126/sciadv.aed1757
Vancouver
Guo C, Zhang S, Yerramsetti R, Zhang J, Guan X, Yang R, et al. Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science Advances. 2026. doi:10.1126/sciadv.aed1757
BibTeX
@article{Guo2026,
author = {Guo, Chong and Zhang, Shuo and Yerramsetti, Ramachandra and Zhang, Jiongyu and Guan, Xin and Yang, Rui and Hou, Chengyu and Pei, Minjie and Schalper, Kurt T and Liu, Xingye and Li, Ziyue and Perpetua, Lorrie and Gan, Wenqi and Ibrahim, Omar and Clark, Rachael A and Liu, Changchun},
title = {Single-nucleotide variant profiling in liquid biopsy with RECO-Cas},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed1757}
}
EUVIMED